- Previous Close
28.34 - Open
28.29 - Bid 28.61 x 4000
- Ask 28.66 x 3100
- Day's Range
28.24 - 28.58 - 52 Week Range
25.20 - 33.92 - Volume
24,554,631 - Avg. Volume
31,631,876 - Market Cap (intraday)
161.954B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.46 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield 1.68 (5.88%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
33.34
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.com88,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PFE
View MorePerformance Overview: PFE
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFE
View MoreValuation Measures
Market Cap
161.95B
Enterprise Value
223.53B
Trailing P/E
--
Forward P/E
10.20
PEG Ratio (5yr expected)
0.22
Price/Sales (ttm)
2.93
Price/Book (mrq)
1.85
Enterprise Value/Revenue
4.05
Enterprise Value/EBITDA
40.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.70%
Return on Assets (ttm)
0.94%
Return on Equity (ttm)
-2.74%
Revenue (ttm)
55.17B
Net Income Avi to Common (ttm)
-2.59B
Diluted EPS (ttm)
-0.46
Balance Sheet and Cash Flow
Total Cash (mrq)
7.1B
Total Debt/Equity (mrq)
79.41%
Levered Free Cash Flow (ttm)
3.44B
Research Analysis: PFE
View MoreCompany Insights: PFE
PFE does not have Company Insights
Research Reports: PFE
View MorePfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, new wave of GLP-1 anti-obesity drugs may tilt the scales; US refiners' margins fading but valuations remain high; Boeing machinists union strike is unfortunate Blow; and Moderna, China Suntien Green Energy, and Mastercard.
Large Cap US Pick List - September 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Stocks could be in another holding period after eight straight days of gains for the major indices.
Stocks could be in another holding period after eight straight days of gains for the major indices. In addition, the FOMC minutes from the July 30/31 meeting drop today at 2:00 pm, Jackson Hole and Chairman Powell take center stage on Friday, and a critical EPS report from NVDA comes next Wednesday. The major indices saw modest losses on Tuesday (between 0.2% and 0.3%). Once again, the small-caps took the brunt of the selling, with the Russell 2000 and S&P 600 both falling slightly more than 1%, and the S&P MidCap 400 dropping 0.9%. It was the weakest NYSE breadth day since the panic on August 5. Sector leadership (if you can call it that) was provided by defensive Staples (+0.5%) and Healthcare (+0.4%). Seven sectors saw losses of less than 0.4%. Energy was the big loser, giving up 2.6% as WTI fell back to the $73 region and close to the lows seen in early August. The Nasdaq 100 (QQQ) McClellan Oscillator (market breadth indicator) has traced out a breadth thrust as the oscillator jumped to +90 from -76 in 10 trading days. The indicator also went from below its lower Bollinger Band to above its upper band. We saw a similar combination of moves back in October/November 2023, just when the QQQ started a big move higher. We also have seen similar moves by the oscillator for the S&P 500, with a nice rebound from the S&P 100 as the oscillator rose to +86 from -69. Seasonality is tricky this time of year due to low liquidity. However, there is a weak period just ahead, namely the second half of September. And that is true whether we look at the past 30 years or the past 50 years. (Mark Arbeter, CMT)
Top Analysts: PFE
View MoreOverall Score
Discover which analysts rank highest for PFE overall weighted by direction, price target, and price movement.
Learn MoreDirection Score
Discover which analysts rank highest on predicting the directional movement of PFE.
Learn MorePrice Score
Discover which analysts rank highest on predicting the price target of PFE.
Learn More